VPRIV

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
IB/0070	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	15/11/2024	n/a		
II/0063	Update of section 4.2 of the SmPC in order to add information to support at-home self-administration of	14/11/2024	15/01/2025	SmPC, Annex II and PL	Home administration by a healthcare professional or self-administration (i.e. administration by the patient's

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	VPRIV by a trained patient and/or a caregiver based on post-marketing data and literature. The Package Leaflet and Annex IID are updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC and Package Leaflet and to update the contact details of the local representatives in the Package Leaflet. The updated RMP version 13.4 was agreed during the procedure. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				caregiver or by the patients themselves) may be considered for patients who have received at least three infusions and who tolerated their infusions well. The decision to have a patient move to home infusion should be made after evaluation and recommendation by the treating physician. Self administration in particular should be closely monitored by the treating physician and should occur in the presence of a responsible adult. The treating physician has to make sure that the one who will administer velaglucerase alfa in the home setting is appropriately trained. Dose and infusion rate should remain constant while at home, and not be changed without supervision of the treating physician. For more information, please refer to the Summary of Product Characteristics.
PSUSA/3103/ 202402	Periodic Safety Update EU Single assessment - velaglucerase alfa	03/10/2024	n/a		PRAC Recommendation - maintenance
IA/0069/G	This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters	26/08/2024	n/a		

	and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new				

	specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting				

	material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of				

	an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)				
IB/0067	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	27/03/2024	n/a		
II/0061	Update of section 4.4 of the SmPC, based on a review of post-marketing data and literature, to add further information regarding the fact that the development of antibodies to velaglucerase alfa may be associated with infusion-related reactions including allergic-type hypersensitivity reactions, and guidance regarding how to request antibody testing services in the clinical setting. Further, Annex IID of the PI was updated to delete the key elements concerning antibody testing. An updated RMP version 12.2 was agreed during the procedure and the proposal to remove certain risks from the list of safety concerns was endorsed, i.e. risks related to 'Reduced Efficacy due to neutralizing antibodies',	11/01/2024	15/01/2025	SmPC and Annex II	n/a

	'Use in patients with a history of adverse drug reactions in other Enzyme Replacement Therapies', 'Adverse events during off-label use' and 'Activated partial thromboplastin time'. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				
IB/0066	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	14/12/2023	n/a		
IA/0065	B.II.f.1.e - Stability of FP - Change to an approved stability protocol	20/11/2023	n/a		
IA/0064	B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits	09/10/2023	n/a		
IB/0062	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	22/09/2023	n/a		
II/0054	Update of section 5.1 of the SmPC to reflect the results of study SHP-GCB-402: A multicenter, open-	25/05/2023	01/12/2023	SmPC and PL	Study 402 was a Phase IV, open-label, single-arm study that evaluated the effect of VPRIV on bone-related

	label, single-arm, phase 4 study designed to prospectively evaluate the effects of VPRIV on bone-related pathology in treatment-naïve subjects with type 1 Gaucher disease. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority				pathology in 21 treatment naïve adult subjects with type 1 Gaucher disease. The primary efficacy analysis was conducted in 16 subjects that completed 24 months of VPRIV treatment with a median age of 46 years at baseline and baseline mean (SD) BMD Z score of -1.93 (0.876). In this study, the primary efficacy endpoint was the change from baseline to 24 months in LS BMD Z score as measured by the DXA method. A positive trend for the primary efficacy endpoint was seen [change in LS BMD Z score baseline to 24 months mean (SD) 0.17 (0.394), 95% CI -0.04, 0.38; but the effect was not statistically significant (p-value 0.1077). No relevant effect of VPRIV on LS BMD Z score was seen after 1 year of treatment. The safety profile was consistent with data from previous studies as well; no new safety signals were observed.
PSUSA/3103/202202	Periodic Safety Update EU Single assessment - velaglucerase alfa	27/10/2022	n/a		PRAC Recommendation - maintenance
IAIN/0060/G	This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.1 - Administrative change - Change in the name and/or address of the MAH	19/10/2022	01/12/2023	SmPC, Annex II, Labelling and PL	
IB/0059	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	11/10/2022	n/a		
N/0058	Minor change in labelling or package leaflet not	14/09/2022	28/10/2022	PL	

	connected with the SPC (Art. 61.3 Notification)				
II/0055	B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability	01/09/2022	n/a		
II/0049	Submission of final physician data study results for PASS study "Evaluation of the Effectiveness of Risk Minimisation Measures: A Survey among Health Care Professionals and Patient/Caregivers to Assess their Knowledge and Attitudes on Prescribing and Home Administration Conditions of Velaglucerase Alpha (VPRIV®) in 6 European Countries" (EUPASS 14255). An updated RMP version 11.0 was agreed during the procedure, and Annex II was updated accordingly to include new agreed key elements for the educational material. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	07/07/2022	28/10/2022	Annex II	n/a
IAIN/0053/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer	22/11/2021	28/10/2022	Annex II and PL	

	responsible for importation and/or batch release - Not including batch control/testing				
T/0052	Transfer of Marketing Authorisation	13/08/2021	29/09/2021	SmPC, Labelling and PL	
II/0051	B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS	18/02/2021	n/a		
II/0048	Update of section 4.4 of the SmPC to include information on 1 additional patient with IgG anti-velaglucerase antibodies with neutralizing activity reported during extension Study HGT-GCB-044, and to include vomiting as an infusion-related reaction that has been reported in post-marketing experience. Further, the MAH is updating the instructions in sections 4.2 and 6.6 of the SmPC to state that a 0.2 µm filter and a 0.22 µm filter are both considered acceptable when administering the product. In addition, the MAH implemented minor editorial changes in SmPC section 5.1 and a clarification that paediatric patients included in the studies were 4 years of age and older. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance	28/01/2021	29/09/2021	SmPC and PL	During a post-marketing extension study, one patient developed IgG antibodies to Vpriv. In addition, a few events of positive neutralising antibodies and lack of effect were reported post-marketing.

	data				
IB/0050	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	23/10/2020	n/a		
PSUSA/3103/ 202002	Periodic Safety Update EU Single assessment - velaglucerase alfa	01/10/2020	n/a		PRAC Recommendation - maintenance
R/0045	Renewal of the marketing authorisation.	28/05/2020	23/07/2020	SmPC, Annex II and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of VPRIV in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
IB/0044	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	18/02/2020	n/a		
IB/0043/G	This was an application for a group of variations. B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	14/02/2020	n/a		
IB/0046	B.II.b.5.c - Change to in-process tests or limits	06/02/2020	n/a		

	applied during the manufacture of the finished product - Deletion of a non-significant in-process test				
IAIN/0042/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	14/10/2019	n/a		
IB/0040	To update sections 4.4 and 4.8 of the SmPC to add "vomiting" and "blurred vision" as additional adverse drug reactions following outcome of assessment of post-authorisation measure LEG 027. In addition, the MAH took the opportunity to fix formatting to section 6.3 of the SmPC. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	25/06/2019	18/06/2020	SmPC and PL	
IB/0039/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch	06/06/2019	n/a		

	control/testing takes place				
IB/0038/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	15/02/2019	n/a		
PSUSA/3103/201802	Periodic Safety Update EU Single assessment - velaglucerase alfa	04/10/2018	n/a		PRAC Recommendation - maintenance
IAIN/0036/G	This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	16/04/2018	28/03/2019	SmPC, Annex II, Labelling and PL	
II/0035	B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product	15/03/2018	n/a		

IB/0034	B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	05/05/2017	n/a		
IA/0033	A.7 - Administrative change - Deletion of manufacturing sites	15/09/2016	n/a		
PSUSA/3103/ 201602	Periodic Safety Update EU Single assessment - velaglucerase alfa	02/09/2016	n/a		PRAC Recommendation - maintenance
II/0032	Update of section 5.1 of the SmPC in order to reflect the results of study HGT-GCB-068, a multi-center, open label efficacy and safety study of velaglucerase alfa in children and adolescents with Type 3 Gaucher Disease. The study HGT-GBR-068 is part of the PIP P/0157/2012 studies. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	21/07/2016	25/08/2016	SmPC	
II/0029	C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	28/04/2016	09/06/2016	Annex II	
IA/0030	B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits	18/03/2016	n/a		

II/0022	Update of the SmPC section 4.4 with information on hypersensitivity reactions including symptoms consistent with anaphylaxis; and of SmPC section 4.8 to include 3 new adverse drug reactions (ADRs): chest discomfort, dyspnoea, and pruritus with the frequency common as symptoms of infusion-related reactions (IRRs) occurring in post-marketing experience and to precise the types of hypersensitivity reactions based on the review of post-marketing safety data. A minor consequential change is introduced in section 4.2 of the SmPC. The Package Leaflet (PL) is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	19/11/2015	09/06/2016	SmPC and PL	
IG/0621	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	16/10/2015	n/a		
IAIN/0027	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	30/09/2015	09/06/2016	Annex II and PL	
PSUSA/3103/ 201502	Periodic Safety Update EU Single assessment - velaglucerase alfa	10/09/2015	n/a		PRAC Recommendation - maintenance

IB/0025/G	This was an application for a group of variations. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits	08/09/2015	n/a		
IB/0026/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new	24/08/2015	n/a		

	specification parameter to the specification with its corresponding test method				
R/0021	Renewal of the marketing authorisation.	23/04/2015	19/06/2015	Labelling and PL	Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of VPRIV continues to be favourable. It is expected that additional data from a registry called Gaucher observational study (GOS) will provide additional information on Infusion-related reactions (IRR) including hypersensitivity reactions and anaphylaxis, and the additional information expected on the connection or non-connection of IRR to antibody development as well as the comparison with alternative treatments is expected to provide information on risk factors that will facilitate more focussed risk minimisation measures. Therefore the CHMP was of the view that one additional five-year renewal on the basis of pharmacovigilance grounds was required.
II/0020/G	This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range	21/05/2015	n/a		

IAIN/0024	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	19/05/2015	n/a		
PSUV/0018	Periodic Safety Update	11/09/2014	n/a		PRAC Recommendation - maintenance
IB/0017	B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)	04/04/2014	n/a		
IB/0016/G	This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised	19/12/2013	n/a		
II/0015	Update of section 5.1 of the SmPC to include new long-term clinical safety and efficacy data collected in study HGT-GCB-044. Further, an update of section 4.6 of the SmPC was based on composite clinical and post-marketing data on drug exposure during pregnancy from the date of the initial marketing authorisation through 15 Jul 2013. The Package	19/12/2013	27/01/2015	SmPC and PL	This variation concerned the update of the Product Information with new, long-term clinical safety and efficacy data collected in study HGT-GCB-044. Study HGT-GCB-044 was an open-label extension of the 3 parent registration studies TKT032, TKT034, and HGT-GCB-039 with the primary objective to evaluate the long-term safety of velaglucerase alfa every other week in patients with type 1

	Leaflet has been updated accordingly. Furthermore, the MAH proposed this opportunity to bring section 4.8 of the SmPC in line with the latest QRD template version 9.0. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				Gaucher disease. Secondary objectives were evaluation of the effects of velaglucerase alfa on clinical parameters of Gaucher disease, including haemoglobin concentration, platelet count, liver volume by MRI, and spleen volume by MRI in patients who had not undergone splenectomy. Further, an update of SPC section 4.6 is proposed based on composite clinical and post-marketing data on drug exposure during pregnancy from the date of the initial marketing authorisation through 15 July 2013.
IA/0013/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits	05/08/2013	n/a		
II/0012	Update of section 5.1 of the SmPC to include information on new clinical data collected in the clinical study TKT025EXT. Furthermore, the MAH took the opportunity to update Annex II in accordance with the QRD template. The variation concerned amendments to the Summary of Product Characteristics and Annex II.	21/03/2013	20/12/2013	SmPC and Annex II	In this variation the MAH submitted data from the finalised clinical study TKT025EXT (extension study of TKT025) and from the ongoing study HGT-GCB-044. In trial TKT025EXT, the clinically meaningful and statistically significant improvements in haemoglobin concentration, platelet count, normalised liver and spleen volumes (MRI), skeletal pathology, and reduction in the plasma biomarkers chitriosidase and CCL18 achieved in the

	C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data				parent study TKT025 were further improved or sustained during the extension. Regarding study HGT-GCB-044, the interpretation of the results of the submitted 2-year interim report is considered limited by the CHMP since the analysis has not been prespecified and the trial is currently ongoing. The provided data do not indicate a change in the AE profile of velaglucerase alfa. No new or unexpected safety signals have been reported through the long-term safety extensions. The CHMP agreed that section 5.1 of the SmPC is updated to include information on the clinical data collected in study TKT025EXT. However, regarding study HGT-GCB-044 the CHMP considered that the interpretation of the results of this 2-years exposure interim report is limited and requested that a variation to add data on this study in the product information will be submitted in the future when the final study report becomes available. The CHMP was of the opinion that this data do not affect the benefit/risk balance of Vpriv (velaglucerase) indicated for long-term enzyme replacement therapy (ERT) in patients with type 1 Gaucher disease (GD).
WS/0291	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	21/02/2013	n/a		

IB/0011	C.I.7.b - Deletion of - a strength	21/12/2012	20/12/2013	SmPC, Labelling and PL	
IG/0216	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	14/09/2012	n/a		
II/0006	This type II variations concerns update of the Patient Information reflecting the results from the clinical study HGT-GCB-058 conducted in fulfilment of FUM009. Sections 4.2, 4.8, and 5.1 of the SmPC are affected. The Package Leaflet is updated accordingly. Furthermore, the PI is being brought in line with the latest QRD template version 8. The requested variation proposed amendments to the Summary of Product Characteristics, Annex II, Labelling and Package Leaflet. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data	24/05/2012	27/06/2012	SmPC, Annex II, Labelling and PL	Following completion of the clinical study HGT-GCB-058 'A Multicenter Open-Label Treatment Protocol to Observe the Safety of Gene-Activated Human Glucocerebrosidase (GA-GCB, Velaglucerase alfa) Enzyme Replacement Therapy in Newly Diagnosed or Previously Treated (with Imiglucerase) Patients with type 1 Gaucher Disease' additional clinical data especially related to safety and the use of Vpriv in elderly patients became available. In addition to the patient safety assessment conducted as part of the overall clinical assessment, efficacy of velaglucerase alfa in patients switching from imiglucerase was also evaluated. The provided data indicate that efficacy in patients switching ERT from imiglucerase to velaglucerase alfa is maintained, while for treatment-naïve patients these parameters indicate improvement with velaglucerase treatment. There are no new or unexpected findings regarding the efficacy or safety of velaglucerase alfa. The CHMP was of the opinion that this information is of importance to the prescribers and the patients and addition of appropriate wording in the PI of Vpris is therefore agreed. The overall benefit risk balance remains positive.
II/0007/G	This was an application for a group of variations. To introduce additional manufacturing facilities	21/06/2012	21/06/2012		

	involved in the manufacturing process of the finished product. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/immunological medicinal products. B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing				

	takes place				
IG/0175/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)	04/06/2012	04/06/2012	Annex II	
II/0005/G	This was an application for a group of variations. To change the specification limits for the active substance and the finished product outside the approved specifications limits range. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range	19/04/2012	n/a		
II/0004	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	16/02/2012	26/03/2012	Annex II and PL	

II/0002	To introduce a new filling line for the finished product. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/immunological medicinal products.	17/02/2011	11/03/2011		
IG/0029	A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)	02/12/2010	n/a		
IB/0001/G	This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside	03/11/2010	03/11/2010	SmPC, Labelling and PL	

	the range of the currently approved pack sizes				